Efficacy and safety of cinobufacini injection combined with vinorelbine and cisplatin regimen chemotherapy for stage III/IV non-small cell lung cancer: A protocol for systematic review and meta-analysis of randomized controlled trials.
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Bufanolides
/ administration & dosage
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Cisplatin
/ therapeutic use
Drugs, Chinese Herbal
/ administration & dosage
Humans
Lung Neoplasms
/ drug therapy
Neoplasm Staging
Randomized Controlled Trials as Topic
Research Design
Vinorelbine
/ therapeutic use
Meta-Analysis as Topic
Systematic Review as Topic
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
31 Jul 2020
31 Jul 2020
Historique:
entrez:
7
8
2020
pubmed:
7
8
2020
medline:
25
8
2020
Statut:
ppublish
Résumé
The main component of cinobufacini injection is dry toad skin, which is used as adjuvant therapy for stage III/IV non-small cell lung cancer patients in long-term combination with vinorelbine and cisplatin. However, the efficacy and safety of this combination therapy remain unclear. A systematic review and meta-analysis will be conducted following the preferred reported items for systematic review and meta-analysis guidelines. Two independent reviewers (LRL and ZLN) will carry out a comprehensive search of the PubMed, Web of Science, Cochrane Library, EMBASE, the Chinese Science and Technology Periodical Database, China National Knowledge Infrastructure, Wanfang Databases, China Biology Medicine. The last search date will be July 30, 2020. Reference list of all selected articles will independently screened to identify additional studies left out in the initial search. The Cochrane Risk of Bias Tool will be used to evaluate the risk of bias of the randomized controlled trials. Outcome index: The main efficacy indicators were based on the objective efficacy evaluation criteria of the World Health Organization antineoplastic drugs or the objective efficacy evaluation criteria of solid tumors established by RECIST. Secondary criteria Karnofsky performance scale (KPS) score, pain efficacy criteria, side effects of chemotherapy such as myelosuppression and gastrointestinal symptoms. Assessment of risk of bias and data synthesis will be conducted using Review Manager V5.3 software. This study will systematically evaluate the efficacy and safety of cinobufacini combined with vinorelbine and cisplatin in the treatment of stage III/IV non-small cell lung cancer. The results of this systematic review will be published in peer-reviewed scientific journals. The ethical approval is not required since systematic review is based on published studies. INPLASY202060091.
Sections du résumé
BACKGROUND
BACKGROUND
The main component of cinobufacini injection is dry toad skin, which is used as adjuvant therapy for stage III/IV non-small cell lung cancer patients in long-term combination with vinorelbine and cisplatin. However, the efficacy and safety of this combination therapy remain unclear.
METHODS
METHODS
A systematic review and meta-analysis will be conducted following the preferred reported items for systematic review and meta-analysis guidelines. Two independent reviewers (LRL and ZLN) will carry out a comprehensive search of the PubMed, Web of Science, Cochrane Library, EMBASE, the Chinese Science and Technology Periodical Database, China National Knowledge Infrastructure, Wanfang Databases, China Biology Medicine. The last search date will be July 30, 2020. Reference list of all selected articles will independently screened to identify additional studies left out in the initial search. The Cochrane Risk of Bias Tool will be used to evaluate the risk of bias of the randomized controlled trials. Outcome index: The main efficacy indicators were based on the objective efficacy evaluation criteria of the World Health Organization antineoplastic drugs or the objective efficacy evaluation criteria of solid tumors established by RECIST. Secondary criteria Karnofsky performance scale (KPS) score, pain efficacy criteria, side effects of chemotherapy such as myelosuppression and gastrointestinal symptoms. Assessment of risk of bias and data synthesis will be conducted using Review Manager V5.3 software.
RESULTS
RESULTS
This study will systematically evaluate the efficacy and safety of cinobufacini combined with vinorelbine and cisplatin in the treatment of stage III/IV non-small cell lung cancer. The results of this systematic review will be published in peer-reviewed scientific journals.
ETHICS
METHODS
The ethical approval is not required since systematic review is based on published studies.
INPLASY REGISTRATION NUMBER
UNASSIGNED
INPLASY202060091.
Identifiants
pubmed: 32756206
doi: 10.1097/MD.0000000000021539
pii: 00005792-202007310-00136
pmc: PMC7402891
doi:
Substances chimiques
Bufanolides
0
Drugs, Chinese Herbal
0
Cisplatin
Q20Q21Q62J
Vinorelbine
Q6C979R91Y
cinobufagin
T9PSN4R8IR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e21539Références
JAMA. 2019 Aug 27;322(8):764-774
pubmed: 31454018
Onco Targets Ther. 2016 Apr 19;9:2359-64
pubmed: 27143931
Food Chem Toxicol. 2012 Feb;50(2):295-302
pubmed: 22019693
J Thorac Oncol. 2010 Oct;5(10):1529-35
pubmed: 20631635
Nature. 2018 Jan 24;553(7689):446-454
pubmed: 29364287
Oncologist. 2008;13 Suppl 1:5-13
pubmed: 18263769
Biosci Trends. 2018;12(3):220-239
pubmed: 30012913
Support Care Cancer. 2014 May;22(5):1417-28
pubmed: 24563068
Evid Based Complement Alternat Med. 2018 Sep 4;2018:7362340
pubmed: 30254688
J Tradit Chin Med. 2020 Apr;40(2):167-187
pubmed: 32242383
Biosci Trends. 2010 Dec;4(6):297-307
pubmed: 21248427
Complement Ther Med. 2016 Feb;24:55-62
pubmed: 26860802
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Expert Rev Anticancer Ther. 2016 Jun;16(6):653-60
pubmed: 27010977
Biosci Trends. 2015 Feb;9(1):16-34
pubmed: 25787906
Allergy. 2009 May;64(5):669-77
pubmed: 19210357
Semin Oncol. 2017 Jun;44(3):163-177
pubmed: 29248128
Adv Exp Med Biol. 2016;893:1-19
pubmed: 26667336
BMC Complement Altern Med. 2014 Dec 13;14:483
pubmed: 25496480
Oncol Rep. 2012 May;27(5):1619-24
pubmed: 22267101
Ann Oncol. 2015 Aug;26(8):1573-88
pubmed: 25897013
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nature. 2014 Sep 11;513(7517):S1
pubmed: 25208065
Cancer Med. 2019 May;8(5):1958-1975
pubmed: 30945475
Transl Lung Cancer Res. 2016 Jun;5(3):288-300
pubmed: 27413711